APPROVAL AND SALES RULES
Is Ipamorelin FDA-approved, and can pharmacies mix it?
No. The patient trial failed, pharmacy rules tightened in 2024, and sports groups ban the drug.
The short answer: Ipamorelin was never approved
The Danish team hoped Ipamorelin would give a clean growth-hormone rise with no stress-hormone surge. The later hospital trial didn't help surgery patients, so drug development ended [3].
I checked the federal record for a plain answer. Ipamorelin has never been approved for any illness.
It isn't an approved prescription medicine in any country. The drug failed to show that it helped patients.
Approval would mean that officials had reviewed proof of benefit, harm, and consistent drug making for a stated use. Ipamorelin never reached that point, which matters when a seller calls it medicine for you.
In 2024, federal officials also tightened rules for pharmacies making custom prescriptions. Ipamorelin remains an unapproved lab drug.
Why the failed patient trial blocked approval
Approval requires proof that a drug helps patients without undue harm. After lab work in 1998 [1] and a timing test in 1999 [2], researchers ran a Phase 2 trial, an early test in sick people [3].
The drug's backers stopped after that trial found no benefit. They never paid for a Phase 3 trial, the large patient test usually needed before approval [3].
A larger trial might have found uncommon harms and shown whether any benefit held up in more people. Since that work never happened, doctors can't answer those questions for you.
So “unapproved” means more than unfinished forms. Ipamorelin failed its one patient trial and never proved that it works.
What happened in the bowel-surgery patient trial
The key trial included 114 hospital patients after bowel surgery [3]. Doctors put Ipamorelin into a vein, hoping the patients' bowels would wake sooner.
The patients recovered no faster than those given a placebo, or dummy treatment [3]. After that result, the drug's backer ended the human work.
Doctors gave the medicine by vein twice each day, not as the skin shot promoted for home use. Neither route has proved a benefit to your health.
There is no approved Ipamorelin medicine for a doctor to prescribe. Online sellers are offering a drug that didn't help in its patient trial.
What the 2024 pharmacy decision means for patients
In 2024, federal officials tightened rules for pharmacies that make custom prescriptions. FDA's page current as of April 22, 2026 lists the withdrawn 503A request for ipamorelin acetate, the form pharmacies had asked to use for individual patients, with safety concerns still beside it. Ipamorelin acetate remains in Category 2 under 503B, which covers outsourcing facilities. That withdrawn request by itself gives a pharmacy no answer about whether it can make the drug for a patient.
The planned federal panel still met on October 29, 2024. It reviewed the plain drug and the pharmacy form, but neither became an approved ingredient for custom prescriptions.
A custom prescription is made by a pharmacy for one patient's needs instead of arriving as a factory-made drug. That process doesn't turn an unapproved ingredient into an approved medicine.
Licensed pharmacies therefore don't have federal approval to make Ipamorelin vials for patients. What remains online is unapproved research powder.
What sports rules ban and what urine screens find
Sports rules ban Ipamorelin during both training and contests. The World Anti-Doping Agency lists it as a banned growth drug [7].
Urine screening can pick out very small remains. One method checks Ipamorelin beside 17 other banned growth drugs days after a shot [9].
The rule and the medical approval question are separate. A drug can be unapproved for patients and also banned from sport, as Ipamorelin is.
In a separate case, border agents seized a changed form of the drug [7]. That seizure shows official interest, while the urine study explains sports testing.